A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
Abstract Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotop...
Збережено в:
| Автори: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Nature Portfolio
2023-09-01
|
| Серія: | Communications Biology |
| Онлайн доступ: | https://doi.org/10.1038/s42003-023-05320-0 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
